Olivia Domanski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Olivia Domanski has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Magalie Ladouceur
Department of Congenital Heart Diseases, Hôpital Marie Lannelongue , 14 Avenue Galilée, 92350 Le Plessis-Robinson
2 shared publications - Sébastien Hascoët
Congenital Heart Diseases, M3C Rare Diseases Network, Hôpital Marie‑Lannelongue, France
2 shared publications - Alexandre Delarue
Service de Cardiologie infantile et congénitale CHU de Lille Lille France
1 shared publication Alexis Hermida
UR4666 HEMATIM, équipe CARDIOMICS, Centre Universitaire de Recherche en Santé Université de Picardie Jules Verne Amiens France
1 shared publicationAli Houeijeh
Department of Pediatric and Congenital Heart Disease, University of Lille-Nord de France, France
1 shared publicationAnissa Boubrit
Adult Congenital Heart Disease Unit Hôpital Européen Georges Pompidou Centre de Référence des Malformations Cardiaques Congénitales Complexes Assistance Publique‐Hôpitaux de Paris Paris University Paris France
1 shared publication
Latest Publications
- Open Access
- 13 August 2026
- Published by Wiley in Clinical Genetics
- Vol. 110 (5) , 622-626
Genetic Architecture of Pediatric Cardiomyopathies Assessed by Whole‐Exome Sequencing: Insights Into Early‐Onset and Syndromic Forms
Pediatric cardiomyopathies (CM) are rare and heterogeneous heart disorders, including hypertrophic, dilated, restrictive, arrhythmogenic, and non‐dilated CM. While their genetic basis is well characterized in adults, it remains less clearly defined in children particularly in early‐onset apparently isolated and syndromic forms. We conducted a retrospective study (2018–2024) of 59 pediatric patients who underwent Whole‐Exome Sequencing (WES) for CM at Amiens and Lille University Hospitals, aiming to characterize the genetic architecture of pediatric CM. WES identified at least one Variant Of Interest (VOI) in 62.7% of patients (37/59), including 45.8% (27/59) of P/LP variants, and 16.9% (10/59) of VUS. VOI identification yields for HCM and DCM were respectively 67.7% and 57.1%. Yield was higher in patients diagnosed before 1 year of age compared with those diagnosed later (72.7% vs. 56.7%). Variants were identified in classical CM genes, including sarcomeric genes, but also in less typical and syndromic genes. Among patients diagnosed before 6 months, 55% carried a variant in genes associated with syndromic cardiomyopathy, including cases with initially isolated cardiac phenotypes. These findings support the use of WES as a first‐line approach in pediatric CM and highlight the contribution of complex and syndromic genetic architectures to early‐onset and severe diseases.
- 13 August 2026
- Published by Wiley in Clinical Genetics
- Vol. 110 (5) , 622-626
Open AccessGenetic Architecture of Pediatric Cardiomyopathies Assessed by Whole‐Exome Sequencing: Insights Into Early‐Onset and Syndromic Forms
Pediatric cardiomyopathies (CM) are rare and heterogeneous heart disorders, including hypertrophic, dilated, restrictive, arrhythmogenic, and non‐dilated CM. While their genetic basis is well characterized in adults, it remains less clearly defined in children particularly in early‐onset apparently isolated and syndromic forms. We conducted a retrospective study (2018–2024) of 59 pediatric patients who underwent Whole‐Exome Sequencing (WES) for CM at Amiens and Lille University Hospitals, aiming to characterize the genetic architecture of pediatric CM. WES identified at least one Variant Of Interest (VOI) in 62.7% of patients (37/59), including 45.8% (27/59) of P/LP variants, and 16.9% (10/59) of VUS. VOI identification yields for HCM and DCM were respectively 67.7% and 57.1%. Yield was higher in patients diagnosed before 1 year of age compared with those diagnosed later (72.7% vs. 56.7%). Variants were identified in classical CM genes, including sarcomeric genes, but also in less typical and syndromic genes. Among patients diagnosed before 6 months, 55% carried a variant in genes associated with syndromic cardiomyopathy, including cases with initially isolated cardiac phenotypes. These findings support the use of WES as a first‐line approach in pediatric CM and highlight the contribution of complex and syndromic genetic architectures to early‐onset and severe diseases.
- Open Access
- 18 April 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (8)
Health‐Related Quality of Life and Its Association With Outcomes in Adults With Congenital Heart Disease and Heart Failure: Insight From FRESH‐ACHD Registry
Background: Quality of Life (QoL) is a prognostic factor in heart failure (HF) of patients with acquired cardiac disease. The aim of this study was to determine the predictive value of QoL on outcomes in adults with congenital heart disease (ACHD) and HF. Methods and Results: Quality of life of 196 adults with congenital heart disease with clinical heart failure (HF) (mean age: 44.3±13.8 years; 51% male; 56% with complex congenital heart disease; 47% New York Heart Association class III/IV) included in the prospective multicentric registry FRESH‐ACHD (French Survey on Heart Failure−Adult with Congenital Heart Disease) was assessed using the 36‐Item Short Form Survey (SF‐36), a patient‐reported survey. The primary end point was defined by all‐cause death, HF‐related hospitalization, heart transplantation, and mechanical circulatory support. At 12 months, 28 (14%) patients reached the combined end point. Patients with low quality of life experienced major adverse events more frequently (logrank P =0.013). On univariate analysis, lower score at physical functioning (hazard ratio [HR], 0.98 [95% CI, 0.97–0.99]; P =0.008), role limitations related to physical health (HR, 0.98 [95% CI, 0.97–0.99]; P =0.008), and general health dimensions of the SF‐36 (HR, 0.97 [95% CI, 0.95–0.99]; P =0.002) were significantly predictive of cardiovascular events. However, after multivariable analysis, SF‐36 dimensions were no longer significantly associated with the primary end point. Conclusions: Patients with congenital heart disease with HF and poor quality of life experience severe events more frequently, making quality of life assessment and rehabilitation programs essential to alter their trajectory.
- 18 April 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (8)
Open AccessHealth‐Related Quality of Life and Its Association With Outcomes in Adults With Congenital Heart Disease and Heart Failure: Insight From FRESH‐ACHD Registry
Background: Quality of Life (QoL) is a prognostic factor in heart failure (HF) of patients with acquired cardiac disease. The aim of this study was to determine the predictive value of QoL on outcomes in adults with congenital heart disease (ACHD) and HF. Methods and Results: Quality of life of 196 adults with congenital heart disease with clinical heart failure (HF) (mean age: 44.3±13.8 years; 51% male; 56% with complex congenital heart disease; 47% New York Heart Association class III/IV) included in the prospective multicentric registry FRESH‐ACHD (French Survey on Heart Failure−Adult with Congenital Heart Disease) was assessed using the 36‐Item Short Form Survey (SF‐36), a patient‐reported survey. The primary end point was defined by all‐cause death, HF‐related hospitalization, heart transplantation, and mechanical circulatory support. At 12 months, 28 (14%) patients reached the combined end point. Patients with low quality of life experienced major adverse events more frequently (logrank P =0.013). On univariate analysis, lower score at physical functioning (hazard ratio [HR], 0.98 [95% CI, 0.97–0.99]; P =0.008), role limitations related to physical health (HR, 0.98 [95% CI, 0.97–0.99]; P =0.008), and general health dimensions of the SF‐36 (HR, 0.97 [95% CI, 0.95–0.99]; P =0.002) were significantly predictive of cardiovascular events. However, after multivariable analysis, SF‐36 dimensions were no longer significantly associated with the primary end point. Conclusions: Patients with congenital heart disease with HF and poor quality of life experience severe events more frequently, making quality of life assessment and rehabilitation programs essential to alter their trajectory.
- Top Cited PapersOpen Access
- 26 January 2022
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 219 (3)
Treatment of two infants with PIK3CA-related overgrowth spectrum by alpelisib
PIK3CA-related overgrowth spectrum (PROS) includes rare genetic conditions due to gain-of-function mutations in the PIK3CA gene. There is no approved medical therapy for patients with PROS, and alpelisib, an approved PIK3CA inhibitor in oncology, showed promising results in preclinical models and in patients. Here, we report for the first time the outcome of two infants with PROS having life-threatening conditions treated with alpelisib (25 mg) and monitored with pharmacokinetics. Patient 1 was an 8-mo-old girl with voluminous vascular malformation. Patient 2 was a 9-mo-old boy presenting with asymmetrical body overgrowth and right hemimegalencephaly with West syndrome. After 12 mo of follow-up, alpelisib treatment was associated with improvement in signs and symptoms, morphological lesions and vascular anomalies in the two patients. No adverse events were reported during the study. In this case series, pharmacological inhibition of PIK3CA with low-dose alpelisib was feasible and associated with clinical improvements, including a smaller size of associated complex tissue malformations and good tolerability.
- 26 January 2022
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 219 (3)
Top Cited PapersOpen AccessTreatment of two infants with PIK3CA-related overgrowth spectrum by alpelisib
PIK3CA-related overgrowth spectrum (PROS) includes rare genetic conditions due to gain-of-function mutations in the PIK3CA gene. There is no approved medical therapy for patients with PROS, and alpelisib, an approved PIK3CA inhibitor in oncology, showed promising results in preclinical models and in patients. Here, we report for the first time the outcome of two infants with PROS having life-threatening conditions treated with alpelisib (25 mg) and monitored with pharmacokinetics. Patient 1 was an 8-mo-old girl with voluminous vascular malformation. Patient 2 was a 9-mo-old boy presenting with asymmetrical body overgrowth and right hemimegalencephaly with West syndrome. After 12 mo of follow-up, alpelisib treatment was associated with improvement in signs and symptoms, morphological lesions and vascular anomalies in the two patients. No adverse events were reported during the study. In this case series, pharmacological inhibition of PIK3CA with low-dose alpelisib was feasible and associated with clinical improvements, including a smaller size of associated complex tissue malformations and good tolerability.
- 13 March 2018
- Published by Elsevier in International Journal of Cardiology
- Vol. 261, 54-57
Is the new Occlutech duct occluder an appropriate device for transcatheter closure of patent ductus arteriosus?
- 13 March 2018
- Published by Elsevier in International Journal of Cardiology
- Vol. 261, 54-57
Is the new Occlutech duct occluder an appropriate device for transcatheter closure of patent ductus arteriosus?
- Open Access
- 14 December 2012
- Published by BMJ in BMJ Case Reports
- Vol. 2012
An unexpected rise in cardiac troponin I in a patient with multiple myeloma
- 14 December 2012
- Published by BMJ in BMJ Case Reports
- Vol. 2012
Open AccessAn unexpected rise in cardiac troponin I in a patient with multiple myeloma